Cancer Network spoke with Marleen Meyers, MD, about evidence on low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ.
Cancer Network spoke with Marleen Meyers, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, who specializes in the treatment and care of patients with breast cancer, about the results of a phase III trial, TAM-01. This trial examined the potential benefit of low-dose tamoxifen compared with placebo in women who had surgery for their ductal carcinoma in situ (DCIS). The results of the trial were presented this past December at the annual 2018 San Antonio Breast Cancer Symposium (SABCS).
